Uncategorized
IND active for wet AMD treatment from Regenxbio
An investigational new drug application is now active for a phase 1 trial of the wet age-related macular degeneration treatment RGX-314, according to a press release from Regenxbio.The multicenter, open-label, multiple-cohort, dose-escalation trial is expected to begin enrolling patients mid-year, with an interim update expected by the end of the year.